$VTAK
Catheter Precision, Inc.

2018 Q4 Form 10-K Financial Statement

#000156459019007905 Filed on March 15, 2019

View on sec.gov

Income Statement

Concept 2018 Q4 2018 2017 Q4
Revenue $1.988M $6.257M
YoY Change 6.59%
Cost Of Revenue $1.200M $4.206M
YoY Change 0.98%
Gross Profit $788.0K $2.051M
YoY Change 20.29%
Gross Profit Margin 39.64% 32.78%
Selling, General & Admin $14.81M $30.44M
YoY Change 103.62%
% of Gross Profit 1879.95% 1483.91%
Research & Development $1.244M $2.776M
YoY Change -38.56%
% of Gross Profit 157.87% 135.35%
Depreciation & Amortization $236.0K $624.0K $70.00K
YoY Change 237.14% 186.24%
% of Gross Profit 29.95% 30.42%
Operating Expenses $16.06M $33.21M
YoY Change 70.62%
Operating Profit -$15.27M -$31.16M
YoY Change 75.45%
Interest Expense $340.0K $14.00K
YoY Change 250.0%
% of Operating Profit
Other Income/Expense, Net $338.0K
YoY Change -8550.0%
Pretax Income -$14.93M -$30.82M
YoY Change 73.51%
Income Tax $7.000K $10.00K
% Of Pretax Income
Net Earnings -$14.94M -$30.83M
YoY Change 73.55%
Net Earnings / Revenue -751.36% -492.76%
Basic Earnings Per Share
Diluted Earnings Per Share -$1.178M -$83.32M
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $64.32M $64.31M
YoY Change 680.75%
Cash & Equivalents $64.32M $64.31M $8.237M
Short-Term Investments $0.00
Other Short-Term Assets $1.501M $1.500M
YoY Change 1530.43%
Inventory $2.097M $2.100M $1.196M
Prepaid Expenses
Receivables $1.320M $1.320M $517.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $69.23M $69.23M $10.04M
YoY Change 589.43% 589.4%
LONG-TERM ASSETS
Property, Plant & Equipment $4.757M $4.760M $1.159M
YoY Change 310.44% 310.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $45.00K $40.00K $68.00K
YoY Change -33.82% -41.18%
Total Long-Term Assets $4.802M $4.800M $1.227M
YoY Change 291.36% 291.2%
TOTAL ASSETS
Total Short-Term Assets $69.23M $69.23M $10.04M
Total Long-Term Assets $4.802M $4.800M $1.227M
Total Assets $74.04M $74.03M $11.27M
YoY Change 556.98% 556.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.125M $1.120M $426.0K
YoY Change 164.08% 162.91%
Accrued Expenses $2.809M $2.810M $324.0K
YoY Change 766.98% 767.28%
Deferred Revenue $1.723M $1.714M
YoY Change 0.53%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $293.0K $290.0K
YoY Change 559.09%
Total Short-Term Liabilities $5.950M $5.950M $2.633M
YoY Change 125.98% 125.98%
LONG-TERM LIABILITIES
Long-Term Debt $557.0K $560.0K
YoY Change 2847.37%
Other Long-Term Liabilities $56.00K $820.0K $81.00K
YoY Change -30.86% -94.95%
Total Long-Term Liabilities $56.00K $1.380M $81.00K
YoY Change -30.86% -91.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.950M $5.950M $2.633M
Total Long-Term Liabilities $56.00K $1.380M $81.00K
Total Liabilities $7.330M $7.330M $18.88M
YoY Change -61.18% -61.18%
SHAREHOLDERS EQUITY
Retained Earnings -$60.22M -$29.39M
YoY Change 104.91%
Common Stock $126.9M $21.77M
YoY Change 482.92%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $66.73M $66.70M -$7.615M
YoY Change
Total Liabilities & Shareholders Equity $74.04M $74.03M $11.27M
YoY Change 556.98% 556.93%

Cashflow Statement

Concept 2018 Q4 2018 2017 Q4
OPERATING ACTIVITIES
Net Income -$14.94M -$30.83M
YoY Change 73.55%
Depreciation, Depletion And Amortization $236.0K $624.0K $70.00K
YoY Change 237.14% 186.24%
Cash From Operating Activities -$8.399M -$18.51M -$1.500M
YoY Change 459.93% 235.11%
INVESTING ACTIVITIES
Capital Expenditures -$158.0K $582.0K -$270.0K
YoY Change -41.48% 6.4%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$158.0K -$582.0K -$270.0K
YoY Change -41.48% 6.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $78.81M
YoY Change 655.57%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 67.96M 75.17M 9.050M
YoY Change 650.91% 623.74%
NET CHANGE
Cash From Operating Activities -8.399M -18.51M -1.500M
Cash From Investing Activities -158.0K -582.0K -270.0K
Cash From Financing Activities 67.96M 75.17M 9.050M
Net Change In Cash 59.40M 56.08M 7.280M
YoY Change 715.93% 1199.3%
FREE CASH FLOW
Cash From Operating Activities -$8.399M -$18.51M -$1.500M
Capital Expenditures -$158.0K $582.0K -$270.0K
Free Cash Flow -$8.241M -$19.09M -$1.230M
YoY Change 570.0% 214.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2017 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4165000
CY2018 us-gaap Gross Profit
GrossProfit
2051000
CY2017 us-gaap Gross Profit
GrossProfit
1705000
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
30435000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6257000
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5870000
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4206000
CY2017 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14947000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2776000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4518000
CY2018 us-gaap Operating Expenses
OperatingExpenses
33211000
CY2017 us-gaap Operating Expenses
OperatingExpenses
19465000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-31160000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-17760000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-30832000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
21773000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60221000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-29389000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
66705000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-7615000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
74035000
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
45000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
68000
CY2018Q4 us-gaap Assets
Assets
74035000
CY2017Q4 us-gaap Assets
Assets
11269000
CY2017Q4 us-gaap Liabilities
Liabilities
18884000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
64315000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8237000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1320000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
517000
CY2018Q4 us-gaap Inventory Net
InventoryNet
2097000
CY2017Q4 us-gaap Inventory Net
InventoryNet
1196000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1501000
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
92000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
69233000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
10042000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4757000
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1159000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1125000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
426000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2809000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
324000
CY2018Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1723000
CY2017Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1714000
CY2018Q4 rmed Equipment Financing Obligations Current
EquipmentFinancingObligationsCurrent
293000
CY2017Q4 rmed Equipment Financing Obligations Current
EquipmentFinancingObligationsCurrent
44000
CY2017Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
125000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5950000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2633000
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
767000
CY2017Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
775000
CY2018Q4 rmed Equipment Financing Obligations Noncurrent
EquipmentFinancingObligationsNoncurrent
557000
CY2017Q4 rmed Equipment Financing Obligations Noncurrent
EquipmentFinancingObligationsNoncurrent
19000
CY2017Q4 us-gaap Deferred Compensation Sharebased Arrangements Liability Classified Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityClassifiedNoncurrent
15376000
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
56000
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
81000
CY2018Q4 us-gaap Liabilities
Liabilities
7330000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
1000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
126925000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11269000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12689251
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7888170
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12689251
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7888170
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
352000
CY2018 us-gaap Interest Expense
InterestExpense
14000
CY2017 us-gaap Interest Expense
InterestExpense
4000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
338000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30822000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17764000
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10000
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-17765000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.34
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.35
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9230000
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7545000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
-380000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10430000
CY2017 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
100000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
78806000
CY2018 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3556000
CY2018 rmed Settlement Of Stock Based Compensation Liability
SettlementOfStockBasedCompensationLiability
18243000
CY2018 rmed Adjustments To Additional Paid In Capital Share Based Compensation Forfeitures Of Liability Classified Awards
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationForfeituresOfLiabilityClassifiedAwards
1313000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10346000
CY2018 rmed Payment For Underwriters Discount
PaymentForUnderwritersDiscount
5338000
CY2018 us-gaap Profit Loss
ProfitLoss
-30832000
CY2017 us-gaap Profit Loss
ProfitLoss
-17765000
CY2018 us-gaap Depreciation
Depreciation
624000
CY2017 us-gaap Depreciation
Depreciation
218000
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
255000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
14728000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
12706000
CY2017 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
100000
CY2017 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-53000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1058000
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
124000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3874000
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
644000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1386000
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
8000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
699000
CY2017 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-47000
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2485000
CY2017 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-95000
CY2017 rmed Payments On Equipment Financing
PaymentsOnEquipmentFinancing
44000
CY2018 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1000
CY2017 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-91000
CY2018 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-150000
CY2017 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
174000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-18508000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5523000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
582000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
547000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-582000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-547000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
78806000
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10430000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3556000
CY2018 rmed Payments On Equipment Financing
PaymentsOnEquipmentFinancing
82000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
75168000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10386000
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
56078000
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
4316000
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3921000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
831000
CY2018 rmed Transfer From Inventories To Property And Equipment For Demonstration Lasers Lasers And Lasers Placed With Customers
TransferFromInventoriesToPropertyAndEquipmentForDemonstrationLasersLasersAndLasersPlacedWithCustomers
2848000
CY2017 rmed Transfer From Inventories To Property And Equipment For Demonstration Lasers Lasers And Lasers Placed With Customers
TransferFromInventoriesToPropertyAndEquipmentForDemonstrationLasersLasersAndLasersPlacedWithCustomers
377000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
11000
CY2017 us-gaap Interest Paid Net
InterestPaidNet
4000
CY2018 us-gaap Income Taxes Paid
IncomeTaxesPaid
5000
CY2017 us-gaap Income Taxes Paid
IncomeTaxesPaid
1000
CY2017 rmed Payment For Underwriters Discount
PaymentForUnderwritersDiscount
0
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:4pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates<font style="font-weight:normal;font-style:normal;">&#8212;The </font><font style="color:#000000;font-weight:normal;font-style:normal;">financial statements of the Company have been prepared by management in accordance with accounting principles generally accepted in the United States of America. The</font><font style="font-weight:normal;font-style:normal;"> preparation of the financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and reported disclosures of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from those estimates. The Company&#8217;s financial statements are based upon a number of estimates, including but not limited to, allowance for doubtful accounts, inventory reserves, reserves for warranty costs, fair value of stock option awards granted and revenue recognition for multiple element arrangements. </font></p>
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1918000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
4337000
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2018 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of credit risk<font style="font-weight:normal;font-style:normal;">&#8212;Credit risk represents the accounting loss that would be recognized at the reporting date if counterparties failed completely to perform as contracted. Concentrations of credit risk that arise from financial instruments exist for groups of customers or counterparties when they have similar economic characteristics that would cause their ability to meet contractual obligations to be similarly affected by changes in economic or other conditions described below. </font></p> <p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments, which potentially subject the Company to concentration of credit risk, consist of cash balances maintained in excess of Federal Depository Insurance Corporation limits, and accounts receivable which have no collateral or security. The Company monitors the financial condition of the banks in which it currently has deposits. The Company has not experienced any significant losses in this respect and believes that it is not exposed to any significant related risk. </p> <p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exposure to losses on accounts receivable is dependent on the individual customer&#8217;s financial condition. The Company monitors its exposure to credit losses and reserves for those accounts receivable that it deems to be not collectible. </p> <p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One of the Company&#8217;s customers represented 10% of accounts receivable as of December 31, 2018. As of December&#160;31, 2017, accounts receivable due from four of the Company&#8217;s customers was 57% of accounts receivable. </p> <p style="margin-top:9pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No individual customer represented greater than 10% of total net revenue for the years ended December&#160;31, 2018 or 2017. </p>
CY2018 us-gaap Income Tax Examination Likelihood Of Unfavorable Settlement
IncomeTaxExaminationLikelihoodOfUnfavorableSettlement
measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.
CY2018Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1333000
CY2017Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
705000
CY2018Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
88000
CY2017Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
110000
CY2018Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
676000
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
381000
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
6070000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
1934000
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
10000000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
12000
CY2016Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
12000
CY2017 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
0
CY2018 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
53000
CY2017 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
214000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.340
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.027
CY2017 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.058
CY2017 rmed Effective Income Tax Rate Reconciliation Tax Cuts And Jobs Act Of2017 Change In Tax Rate
EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017ChangeInTaxRate
-0.186
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.020
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1313000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
775000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1734000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.022
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.195
CY2017 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.212
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
10000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
236000
CY2018Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
112000
CY2017Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
87000
CY2018Q4 rmed Accrued Services Current
AccruedServicesCurrent
963000
CY2017 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
1000
CY2018 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
10000
CY2017 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
1000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6990000
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1994000
CY2017Q4 rmed Accrued Services Current
AccruedServicesCurrent
1000
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13887000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12002000
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P2Y4M24D
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2018 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
The Company is no longer subject to audit by U.S. federal, state and local tax authorities for years before 2014. The Company is not currently under examination by any taxing jurisdiction.
CY2018Q4 us-gaap Income Tax Examination Interest Accrued
IncomeTaxExaminationInterestAccrued
0
CY2018 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
287000
CY2017 us-gaap Product Warranty Accrual Warranties Issued
ProductWarrantyAccrualWarrantiesIssued
198000
CY2018 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
262000
CY2017 us-gaap Product Warranty Accrual Payments
ProductWarrantyAccrualPayments
208000
CY2018 us-gaap Product Warranty Expense
ProductWarrantyExpense
300000
CY2017 us-gaap Product Warranty Expense
ProductWarrantyExpense
200000
CY2018Q4 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
300000
CY2018 us-gaap Line Of Credit Facility Interest Rate During Period
LineOfCreditFacilityInterestRateDuringPeriod
0.045
CY2018 us-gaap Line Of Credit Facility Expiration Date1
LineOfCreditFacilityExpirationDate1
2017-09-01
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
293000
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
292000
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
265000
CY2018Q4 us-gaap Long Term Debt
LongTermDebt
850000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
88000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther
79000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
203000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
142000
CY2018Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
661000
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
697000
CY2018Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
353000
CY2017Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
618000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
6464000
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4314000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
14759000
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7844000
CY2018Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
888000
CY2017Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
5000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
13871000
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7839000
CY2018 rmed Operating Loss Carryforwards Expiration Year
OperatingLossCarryforwardsExpirationYear
2029
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q4 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2018 rmed Income Tax Examination Years Under Examination
IncomeTaxExaminationYearsUnderExamination
2015 and later
CY2017Q4 us-gaap Income Tax Examination Interest Accrued
IncomeTaxExaminationInterestAccrued
0
CY2018Q4 us-gaap Income Tax Examination Penalties Accrued
IncomeTaxExaminationPenaltiesAccrued
0
CY2017Q4 us-gaap Income Tax Examination Penalties Accrued
IncomeTaxExaminationPenaltiesAccrued
0
CY2018 rmed Operating Loss Carryforwards Utilization Period
OperatingLossCarryforwardsUtilizationPeriod
P3Y
CY2017 rmed Operating Lease Abandonment Expense
OperatingLeaseAbandonmentExpense
200000
CY2017 us-gaap Revenues
Revenues
5870000
CY2018 us-gaap Cost Of Revenue
CostOfRevenue
4206000
CY2017 us-gaap Cost Of Revenue
CostOfRevenue
4165000
CY2018 us-gaap Revenues
Revenues
6257000
CY2018Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
0
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
400000
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
500000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
514000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
528000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
432000
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
445000

Files In Submission

Name View Source Status
0001564590-19-007905-index-headers.html Edgar Link pending
0001564590-19-007905-index.html Edgar Link pending
0001564590-19-007905.txt Edgar Link pending
0001564590-19-007905-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g40t1k1ghsiy000001.jpg Edgar Link pending
g40t1k1ghsiy000002.jpg Edgar Link pending
g40t1k1ghsiy000003.jpg Edgar Link pending
g40t1k1ghsiy000004.jpg Edgar Link pending
gjmkddwgta2y000001.jpg Edgar Link pending
gjmkddwgta2y000002.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rmed-10k_20181231.htm Edgar Link pending
rmed-20181231.xml Edgar Link completed
rmed-20181231.xsd Edgar Link pending
rmed-20181231_cal.xml Edgar Link unprocessable
rmed-20181231_def.xml Edgar Link unprocessable
rmed-20181231_lab.xml Edgar Link unprocessable
rmed-20181231_pre.xml Edgar Link unprocessable
rmed-ex1018_132.htm Edgar Link pending
rmed-ex231_205.htm Edgar Link pending
rmed-ex311_201.htm Edgar Link pending
rmed-ex312_200.htm Edgar Link pending
rmed-ex321_202.htm Edgar Link pending
rmed-ex322_203.htm Edgar Link pending
Show.js Edgar Link pending